Johnson & Johnson
NYSE:JNJ
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
142.2123
167.38
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one JNJ stock under the Base Case scenario is 159.64 USD. Compared to the current market price of 155.17 USD, Johnson & Johnson is Undervalued by 3%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Johnson & Johnson
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for JNJ cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Johnson & Johnson, often referred to as J&J, is a global healthcare giant that operates in three main segments: Pharmaceuticals, Medical Devices, and Consumer Health Products. Founded in 1886, the company has built a strong reputation for its innovative products, which range from life-saving prescription medications to everyday consumer items such as Band-Aids and Tylenol. With a commitment to improving health and well-being, J&J has consistently invested in research and development, yielding a robust pipeline of drugs and technologies that address critical health challenges, including oncology, immunology, and infectious diseases. This ongoing innovation positions the company favorably in a...
Johnson & Johnson, often referred to as J&J, is a global healthcare giant that operates in three main segments: Pharmaceuticals, Medical Devices, and Consumer Health Products. Founded in 1886, the company has built a strong reputation for its innovative products, which range from life-saving prescription medications to everyday consumer items such as Band-Aids and Tylenol. With a commitment to improving health and well-being, J&J has consistently invested in research and development, yielding a robust pipeline of drugs and technologies that address critical health challenges, including oncology, immunology, and infectious diseases. This ongoing innovation positions the company favorably in a competitive landscape, ensuring sustained revenue growth and profitability.
For investors, Johnson & Johnson represents a compelling opportunity not only due to its diversified business model but also its robust financial health. The company boasts a history of steady revenue growth, strong cash flow generation, and a reliable dividend, making it a perennial favorite for income-focused investors. While it has faced some legal challenges and market pressures, J&J’s ability to adapt and respond to these issues has underscored its resilience. With a strong balance sheet and a global footprint in the ever-growing healthcare sector, Johnson & Johnson continues to demonstrate why it is often regarded as a cornerstone investment in a well-rounded portfolio.
Johnson & Johnson (J&J) operates through three core business segments, each focusing on different areas of healthcare:
-
Pharmaceuticals: This segment is one of the largest contributors to J&J’s revenue. It encompasses a wide range of products that address various medical conditions, including oncology, immunology, neuroscience, infectious diseases, and cardiovascular health. J&J's pharmaceutical division is known for its innovation, with a strong pipeline of new medications and therapies.
-
Medical Devices: This segment includes a vast array of products used in surgical, orthopaedic, cardiovascular, and neurological procedures, among others. J&J’s medical device division focuses on advancements in technology to improve patient outcomes. This includes areas such as minimally invasive surgery and diagnostics.
-
Consumer Health Products: This segment covers over-the-counter products, personal care items, and other consumer health goods. Known for brands like Johnson's Baby, Tylenol, Band-Aid, and Neutrogena, this division targets everyday health needs and is aimed at consumers seeking trusted solutions for their personal well-being.
These three segments allow Johnson & Johnson to maintain a diverse revenue stream and mitigate risks associated with reliance on a single area of the healthcare market. The company emphasizes innovation and sustainability across all segments to meet changing consumer and healthcare professional needs.
Johnson & Johnson (J&J) enjoys several unique competitive advantages that contribute to its strong position in the healthcare industry:
-
Diverse Product Portfolio: J&J operates in three main segments: Pharmaceuticals, Medical Devices, and Consumer Health Products. This diversification helps mitigate risks associated with reliance on a single market and allows for cross-utilization of research and development.
-
Strong Brand Recognition and Trust: With iconic products like Band-Aid, Tylenol, and Neutrogena, J&J has built significant brand equity. Consumer trust is particularly crucial in health-related fields, giving J&J a competitive edge in customer loyalty and product adoption.
-
Research and Development (R&D) Capabilities: J&J invests heavily in R&D, leading to a robust pipeline of innovative products. Its commitment to innovation positions the company to respond quickly to market needs and health trends, allowing it to stay ahead of competitors.
-
Global Presence: Operating in over 60 countries, J&J has established a substantial international footprint. This global reach enables the company to access new markets, diversify market risks, and benefit from economies of scale.
-
Strong Supply Chain Management: J&J has developed efficient supply chain systems that enhance operational effectiveness and reduce costs. This operational excellence supports scalable production and timely delivery of products.
-
Focus on Quality and Compliance: J&J has a longstanding commitment to quality and adherence to regulatory standards, which not only reduces risk but also enhances reputation. Their stringent quality controls help maintain a competitive edge in safety-conscious markets.
-
Robust Financial Performance: J&J has shown consistent revenue growth and profitability, allowing it to invest in growth initiatives, pay dividends, and undertake strategic acquisitions that enhance its competitive position.
-
Strategic Acquisitions and Partnerships: The company has a history of acquiring complementary businesses and technologies, which has strengthened its product offerings and market positions. This strategy not only broadens their portfolio but also brings innovative capabilities.
-
Commitment to Sustainability: J&J has made significant efforts to align its operations with sustainability goals, appealing to environmentally-conscious consumers and investors. This commitment can enhance brand loyalty and reduce regulatory risks.
-
Strong Talent Pool and Corporate Culture: J&J's focus on fostering talent and promoting a positive corporate culture enables the company to attract and retain skilled professionals. A motivated workforce can lead to improved innovation and customer service.
By leveraging these unique competitive advantages, Johnson & Johnson is able to maintain a strong position in the highly competitive healthcare market.
Johnson & Johnson (J&J), like any large multinational corporation, faces several risks and challenges. Some of these include:
-
Regulatory Challenges: J&J operates in a highly regulated environment, particularly in the pharmaceutical and medical device sectors. Changes in regulations or increasing scrutiny from agencies like the FDA and international regulatory bodies can impact its operations and product approvals.
-
Litigation Risks: The company has faced numerous lawsuits related to its products, including those involving talc powder and opioid-related claims. Continuing or new litigation can lead to significant financial liabilities and reputational damage.
-
Product Recalls and Safety Concerns: Any significant product recall or safety concern can impact consumer trust and sales. J&J has experienced recalls in the past, and maintaining quality control is crucial.
-
Market Competition: J&J faces stiff competition from other pharmaceutical and consumer product companies. Emerging biotech firms and generic drug manufacturers can erode market share and pressure pricing.
-
Innovation and Pipeline Risks: The success of J&J is closely tied to its ability to innovate. Delays in drug development or failure of pipelines can significantly affect future earnings.
-
Supply Chain Disruptions: Global supply chain issues, which have been exacerbated by the COVID-19 pandemic, can lead to production delays and increased costs.
-
Global Health Crises: Events like the COVID-19 pandemic can affect demand for certain products and alter healthcare priorities, impacting sales across their portfolio.
-
Economic Conditions: Global economic downturns can reduce consumer spending on healthcare products, thereby affecting sales in the consumer health segment.
-
Reputation Management: As a leader in healthcare, J&J needs to maintain a positive public image. Any negative press or incidents can lead to long-term reputational damage.
-
Globalization Risks: Operating in multiple countries exposes J&J to geopolitical risks, currency fluctuations, and local market dynamics that can affect profitability.
-
Sustainability and Ethical Considerations: Increasing scrutiny on corporate social responsibility and sustainability can challenge J&J to meet consumer and regulatory expectations regarding environmental impact and ethical practices.
-
Integration of Acquisitions: J&J’s growth strategy includes acquisitions, which can bring challenges in integrating new businesses and ensuring they align with corporate culture and operational standards.
In summary, while Johnson & Johnson has a diversified portfolio and robust market presence, navigating these risks will be crucial for maintaining its competitive edge and long-term growth prospects.
Revenue & Expenses Breakdown
Johnson & Johnson
Balance Sheet Decomposition
Johnson & Johnson
Current Assets | 53.2B |
Cash & Short-Term Investments | 20.3B |
Receivables | 16.2B |
Other Current Assets | 16.8B |
Non-Current Assets | 125B |
Long-Term Investments | 505m |
PP&E | 20.5B |
Intangibles | 84.3B |
Other Non-Current Assets | 19.8B |
Current Liabilities | 51.8B |
Accounts Payable | 9B |
Accrued Liabilities | 33.5B |
Short-Term Debt | 2B |
Other Current Liabilities | 7.3B |
Non-Current Liabilities | 56.4B |
Long-Term Debt | 31.3B |
Other Non-Current Liabilities | 25.1B |
Earnings Waterfall
Johnson & Johnson
Revenue
|
87.7B
USD
|
Cost of Revenue
|
-27B
USD
|
Gross Profit
|
60.7B
USD
|
Operating Expenses
|
-36.5B
USD
|
Operating Income
|
24.2B
USD
|
Other Expenses
|
-9.5B
USD
|
Net Income
|
14.7B
USD
|
Free Cash Flow Analysis
Johnson & Johnson
USD | |
Free Cash Flow | USD |
In Q3 2024, Johnson & Johnson achieved worldwide sales of $22.5 billion, up 6.3% year-over-year. The Innovative Medicine segment led with $14.6 billion in sales, driven by strong performances from key brands like DARZALEX, which grew by 22.9%. Adjusted operational earnings per share (EPS) guidance was raised to $9.91, primarily due to anticipated sales growth of 5.7% to 6.2%. The company plans significant investments to enhance its pipeline, with a focus on innovative products, despite facing headwinds from the talc litigation. The MedTech sector expects operational sales growth around 5%, reflecting a robust operational strategy.
What is Earnings Call?
JNJ Profitability Score
Profitability Due Diligence
Johnson & Johnson's profitability score is 66/100. The higher the profitability score, the more profitable the company is.
Score
Johnson & Johnson's profitability score is 66/100. The higher the profitability score, the more profitable the company is.
JNJ Solvency Score
Solvency Due Diligence
Johnson & Johnson's solvency score is 62/100. The higher the solvency score, the more solvent the company is.
Score
Johnson & Johnson's solvency score is 62/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
JNJ Price Targets Summary
Johnson & Johnson
According to Wall Street analysts, the average 1-year price target for JNJ is 179.79 USD with a low forecast of 156.55 USD and a high forecast of 225.75 USD.
Dividends
Current shareholder yield for JNJ is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
JNJ Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. The company is headquartered in New Brunswick, New Jersey and currently employs 141,700 full-time employees. The firm operates through three segments: Consumer Health, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer Health segment includes a range of products that is focused on personal healthcare used in the skin health/beauty, over-the-counter medicines, baby care, oral care, women’s health and wound care markets. The Pharmaceutical segment is focused on six therapeutic areas: Immunology, Infectious Diseases, Neuroscience, Oncology, Cardiovascular and Metabolism and Pulmonary Hypertension. The Medical Devices segment includes a range of products used in the interventional solutions, orthopaedics, surgery, and vision fields. Its geographic area includes the United States, Europe, Western Hemisphere (excluding the United States), and Africa, Asia and Pacific.
Contact
IPO
Employees
Officers
The intrinsic value of one JNJ stock under the Base Case scenario is 159.64 USD.
Compared to the current market price of 155.17 USD, Johnson & Johnson is Undervalued by 3%.